PrasugrelisathirdgenerationthienopyridineantithromboticthatirreversIBLeinhibitstheADPP2Y12receptor,inhibitingplateletaggregation.Prasugrelisaprodrug;itundergoesrapidhydrolysisandoxidationinvivotoformitsactivemetabolite.Clinically,prasugreldecreasesthepotentialforischemicevents.
| CasNo. | 150322-43-3 |
|---|---|
| Purity | ≥98% |
| Formula | C20H20FNO3S |
| FormulaWt. | 373.44 |
| ChemicalName | 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-ylacetate |
| IUPACName | [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl]acetate |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | Ambient |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | P6903InfoSheetPDF |
|---|
SeccoGG,ParisiR,MirabellaF,etal.P2Y12inhibitors:pharmacologicmechanismandclinicalrelevance.CardiovascHematolAgentsMedChem.2013Jun;11(2):101-5.PMID:22963529
HagiharaK,KazuiM,KuriharaA,etal.Biotransformationofprasugrel,anovelthienopyridineantiplateletagent,tothepharmacologicallyactivemetabolite.DrugMetabDispos.2010Jun;38(6):898-904.PMID:20228231.
ScottDM,NorwoodRM,ParraD.P2Y12inhibitorsincardiovasculardisease:focusonprasugrel.AnnPharmacother.2009Jan;43(1):64-76.PMID:19050170.
